(PharmaNewsWire.Com, September 10, 2018 ) The Digital Landscape Psoriasis Market report analyzes digital activities undertaken by pharma in support of therapies for moderate-to-severe psoriasis (PsO).
Key Leading Companies Mentioned: AbbVie Novartis LEO Pharma Janssen Amgen Celgene Eli Lilly Valeant MSD / Merck Pfizer Sandoz Almirall Sun Pharma
Key Highlights
- US Patients: Strong PsO support for US patients, particularly from AbbVie, Novartis and LEO Pharma; Janssen was most active in 2017, with new branded and unbranded offerings featuring prominent patient advocates; Valeant and Sun Pharma entered the space for the first time. Opportunities exist for a well-integrated unbranded campaign, linked to social media and a mobile app. - US HCPs: Majority of US HCP support in PsO is in the branded space; brand activity seen from Janssen and Valeant following FDA approval of new products in PsO in 2017, and AbbVie updated resources to assist with Humira prescription. Unbranded and mobile app landscapes are sparse; opportunities may exist to develop or sponsor content with trusted non-pharma organizations; social media activity restricted to corporate accounts, with examples of HCP-specific accounts seen in other diseases. - EUCAN Patients: EUCAN PsO patients receive good unbranded, social media and mobile app support, particularly from AbbVie, LEO Pharma and Novartis. High unbranded activity seen in 2017, particularly from Novartis, with many new offerings seen in Spain from a number of companies; new local Facebook accounts seen from Novartis and Janssen. Novartis and LEO Pharma provide local-language mobile apps across EUCAN, with Novartis’ apps the most successful overall. - EUCAN HCPs: Lack of pharma support available to EUCAN HCPs beyond brand sites; new brand offerings seen in Spain from Lilly and LEO Pharma. Unbranded support is weak, with few HCP-specific sites detected; few strong mobile apps for HCPs, with most seen in Spain. Partnerships with non-pharma organizations may offer more effective opportunities to engage with and support HCPs.
- This report analyzes digital activities undertaken by pharma in support of therapies for therapies for moderate-to-severe psoriasis (PsO). - The report includes digital activities directed towards patients and/or HCPs, including branded websites, unbranded disease awareness initiatives, social media and mobile apps. - The report is based on analysis conducted by a combination of GlobalData’s digital and disease-specific teams. It also includes analysis of data licensed from third parties e.g. website traffic, search engine optimization (SEO), digital display advertising, mobile app downloads, and social media interaction. - The geographic scope of the report is the United States, Canada and the 5EU (UK, Germany, France, Italy & Spain), with EUCAN used as an abbreviation for Europe and Canada throughout. - This report covers the research period from January - December 2017.
Reasons to buy
- Our Digital Landscape report provides an analysis of pharma multichannel activity in the digital PsO space, and can assist our pharma clients derive value in a number of ways: - Competitive Intelligence: Track and compare key competitor activity across channels and identify key trends in PsO - Digital Strategy: Strengthen corporate digital excellence, learn from industry best practice, and identify opportunities for novel digital campaigns - Support new brand launch: See best practice examples of pre- and post-launch digital activities, ascertain must-have digital assets for patient and HCP engagement, and assess potential gaps and opportunities for pipeline brands - Business Development & Licensing: Assess topics and trends shaping digital health in PsO and beyond, and learn about key patient and physician online activities in PsO.
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
